{"title":"葡萄糖负荷后胰高血糖素变化率:妊娠期糖尿病个体化治疗的潜在关键。","authors":"Sae Joko, Takuya Hashimoto, Miho Yamashita, Daisuke Tsuriya, Masato Maekawa, Moriya Iwaizumi","doi":"10.1007/s13340-025-00797-y","DOIUrl":null,"url":null,"abstract":"<p><p>Gestational diabetes mellitus (GDM) is a known risk factor for both maternal and fatal complications. Glycemic control in pregnant women is important for preventing these complications. However, the need for insulin therapy in pregnant women is difficult to determine. This study focuses on glucagon, which provides new prospects due to advancement in the measurement assay method for type 2 diabetes. Investigating the dynamics of glucagon in pregnant women will help in the diagnosis of GDM and in identifying those requiring insulin treatment. A total of 58 pregnant women between 24 and 31 weeks of gestation underwent a 75-g glucose tolerance test at our institution between 2013 and 2015. The results showed differences in post-glucose and insulin levels between patients with and without GDM, but not in glucagon levels. However, differences were observed in fasting plasma glucose (79.2 ± 4.2 vs. 85.7 ± 8.5 mg/dL, P = 0.006) and in the glucagon change rates at 15, 30, and 60 min after glucose loading between patients with GDM requiring insulin treatment and those who did not. Using a cutoff value of -0.4566 for the glucagon change rate at 60 min as the predictor for insulin treatment, the sensitivity and specificity were 63.16% and 92.31%, respectively. Overall, the measurement of glucagon during the early post-glucose load period may be useful in predicting insulin therapy requirements in pregnant Asian women with GDM.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13340-025-00797-y.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 2","pages":"348-355"},"PeriodicalIF":1.2000,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954775/pdf/","citationCount":"0","resultStr":"{\"title\":\"Glucagon change rate after glucose load: a potential key for tailoring treatment in gestational diabetes mellitus.\",\"authors\":\"Sae Joko, Takuya Hashimoto, Miho Yamashita, Daisuke Tsuriya, Masato Maekawa, Moriya Iwaizumi\",\"doi\":\"10.1007/s13340-025-00797-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Gestational diabetes mellitus (GDM) is a known risk factor for both maternal and fatal complications. Glycemic control in pregnant women is important for preventing these complications. However, the need for insulin therapy in pregnant women is difficult to determine. This study focuses on glucagon, which provides new prospects due to advancement in the measurement assay method for type 2 diabetes. Investigating the dynamics of glucagon in pregnant women will help in the diagnosis of GDM and in identifying those requiring insulin treatment. A total of 58 pregnant women between 24 and 31 weeks of gestation underwent a 75-g glucose tolerance test at our institution between 2013 and 2015. The results showed differences in post-glucose and insulin levels between patients with and without GDM, but not in glucagon levels. However, differences were observed in fasting plasma glucose (79.2 ± 4.2 vs. 85.7 ± 8.5 mg/dL, P = 0.006) and in the glucagon change rates at 15, 30, and 60 min after glucose loading between patients with GDM requiring insulin treatment and those who did not. Using a cutoff value of -0.4566 for the glucagon change rate at 60 min as the predictor for insulin treatment, the sensitivity and specificity were 63.16% and 92.31%, respectively. Overall, the measurement of glucagon during the early post-glucose load period may be useful in predicting insulin therapy requirements in pregnant Asian women with GDM.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13340-025-00797-y.</p>\",\"PeriodicalId\":11340,\"journal\":{\"name\":\"Diabetology International\",\"volume\":\"16 2\",\"pages\":\"348-355\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-01-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954775/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetology International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s13340-025-00797-y\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetology International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13340-025-00797-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
妊娠期糖尿病(GDM)是已知的产妇和致命并发症的危险因素。孕妇血糖控制对预防这些并发症很重要。然而,孕妇是否需要胰岛素治疗是很难确定的。本研究的重点是胰高血糖素,由于2型糖尿病的测量方法的进展,为胰高血糖素的研究提供了新的前景。研究孕妇胰高血糖素的动态变化将有助于GDM的诊断和确定需要胰岛素治疗的患者。2013年至2015年间,共有58名妊娠24 - 31周的孕妇在我院接受了75克葡萄糖耐量试验。结果显示,GDM患者和非GDM患者的后葡萄糖和胰岛素水平存在差异,但胰高血糖素水平没有差异。然而,空腹血糖(79.2±4.2 vs. 85.7±8.5 mg/dL, P = 0.006)和葡萄糖负荷后15、30和60分钟胰高血糖素变化率在需要胰岛素治疗的GDM患者和不需要胰岛素治疗的患者之间观察到差异。采用60 min胰高血糖素变化率的临界值-0.4566作为胰岛素治疗的预测指标,敏感性和特异性分别为63.16%和92.31%。总之,葡萄糖负荷后早期胰高血糖素的测量可能有助于预测亚洲妊娠期糖尿病妇女的胰岛素治疗需求。补充信息:在线版本包含补充资料,下载地址:10.1007/s13340-025-00797-y。
Glucagon change rate after glucose load: a potential key for tailoring treatment in gestational diabetes mellitus.
Gestational diabetes mellitus (GDM) is a known risk factor for both maternal and fatal complications. Glycemic control in pregnant women is important for preventing these complications. However, the need for insulin therapy in pregnant women is difficult to determine. This study focuses on glucagon, which provides new prospects due to advancement in the measurement assay method for type 2 diabetes. Investigating the dynamics of glucagon in pregnant women will help in the diagnosis of GDM and in identifying those requiring insulin treatment. A total of 58 pregnant women between 24 and 31 weeks of gestation underwent a 75-g glucose tolerance test at our institution between 2013 and 2015. The results showed differences in post-glucose and insulin levels between patients with and without GDM, but not in glucagon levels. However, differences were observed in fasting plasma glucose (79.2 ± 4.2 vs. 85.7 ± 8.5 mg/dL, P = 0.006) and in the glucagon change rates at 15, 30, and 60 min after glucose loading between patients with GDM requiring insulin treatment and those who did not. Using a cutoff value of -0.4566 for the glucagon change rate at 60 min as the predictor for insulin treatment, the sensitivity and specificity were 63.16% and 92.31%, respectively. Overall, the measurement of glucagon during the early post-glucose load period may be useful in predicting insulin therapy requirements in pregnant Asian women with GDM.
Supplementary information: The online version contains supplementary material available at 10.1007/s13340-025-00797-y.
期刊介绍:
Diabetology International, the official journal of the Japan Diabetes Society, publishes original research articles about experimental research and clinical studies in diabetes and related areas. The journal also presents editorials, reviews, commentaries, reports of expert committees, and case reports on any aspect of diabetes. Diabetology International welcomes submissions from researchers, clinicians, and health professionals throughout the world who are interested in research, treatment, and care of patients with diabetes. All manuscripts are peer-reviewed to assure that high-quality information in the field of diabetes is made available to readers. Manuscripts are reviewed with due respect for the author''s confidentiality. At the same time, reviewers also have rights to confidentiality, which are respected by the editors. The journal follows a single-blind review procedure, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. Single-blind peer review is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.